Technical Analysis for GILD - Gilead Sciences, Inc.

Grade Last Price % Change Price Change
C 75.42 -0.17% -0.13
GILD closed down 0.17 percent on Thursday, September 28, 2023, on 66 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Flat

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Inside Day Range Contraction 0.00%
Gapped Up Strength 0.00%
Crossed Above 20 DMA Bullish -0.17%
MACD Bullish Signal Line Cross Bullish -0.17%
20 DMA Resistance Bearish -0.15%
180 Bearish Setup Bearish Swing Setup -0.15%
Gapped Up Strength -0.15%
NR7 Range Contraction 0.79%
Narrow Range Bar Range Contraction 0.79%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
20 DMA Support about 14 hours ago
1.5x Volume Pace about 14 hours ago
10 DMA Resistance about 14 hours ago
Fell Below 20 DMA about 14 hours ago
10 DMA Support about 14 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Gilead Sciences, Inc. Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.


Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Medicine Biopharmaceutical Disease Nasdaq 100 Inflammation Infection Hypertension Cardiovascular Disease Antibiotics Influenza Coronavirus Macular Degeneration Vascular Disease Respiratory Diseases Pulmonary Arterial Hypertension Cystic Fibrosis Liver Disease HIV Immunodeficiency Organic Chemistry Perfusion Oligonucleotide Hepatotoxins Angina Gilead Sciences Prodrugs Retinitis Fungal Infection Fungal Infections Treatment Of Cardiovascular Disease Cytomegalovirus Retinitis Myocardial Perfusion Imaging Oncology Diseases Tenofovir Disoproxil

Is GILD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 87.1507
52 Week Low 59.6987
Average Volume 5,220,527
200-Day Moving Average 78.81
50-Day Moving Average 76.40
20-Day Moving Average 75.44
10-Day Moving Average 75.45
Average True Range 1.18
RSI (14) 47.37
ADX 8.34
+DI 24.74
-DI 25.50
Chandelier Exit (Long, 3 ATRs) 74.21
Chandelier Exit (Short, 3 ATRs) 76.07
Upper Bollinger Bands 77.28
Lower Bollinger Band 73.60
Percent B (%b) 0.49
BandWidth 4.88
MACD Line -0.25
MACD Signal Line -0.27
MACD Histogram 0.0159
Fundamentals Value
Market Cap 94.54 Billion
Num Shares 1.25 Billion
EPS 1.01
Price-to-Earnings (P/E) Ratio 74.90
Price-to-Sales 3.24
Price-to-Book 4.28
PEG Ratio 0.43
Dividend 2.72
Dividend Yield 3.61%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 76.64
Resistance 3 (R3) 76.70 76.37 76.43
Resistance 2 (R2) 76.37 76.06 76.33 76.36
Resistance 1 (R1) 75.89 75.87 75.73 75.83 76.30
Pivot Point 75.56 75.56 75.47 75.52 75.56
Support 1 (S1) 75.08 75.25 74.92 75.02 74.54
Support 2 (S2) 74.75 75.06 74.71 74.48
Support 3 (S3) 74.27 74.75 74.41
Support 4 (S4) 74.21